244 Endometrial Cancer Clinical Trials Recruiting Now (May 2026): MMR Status, Dostarlimab, T-DXd, Selinexor, RAINBO Molecular Classification, MDM2 Navtemadlin

Last updated: May 28, 2026

Current Clinical Trial Landscape

Active research areas in 2026:

Standard of care: First-line advanced: carboplatin/paclitaxel + pembrolizumab or dostarlimab (regardless of MMR status). Second-line dMMR: pembrolizumab or dostarlimab monotherapy. Second-line pMMR: lenvatinib + pembrolizumab. MMR/MSI status and p53 mutation are key biomarkers.

Recruiting Trials by Treatment Setting

Adjuvant — Molecular-Classification-Guided

The biggest adjuvant story in endometrial cancer is treatment-tailoring by molecular classification (TCGA-style 4-group profiling: p53abn / MMRd / NSMP / POLEmut):

Advanced / Recurrent — First-Line

IO + chemo is standard. Trials test ADC additions and novel combinations:

Advanced / Recurrent — Second-Line and Beyond

After first-line IO+chemo failure, HER2-targeted, ADC, and novel agents:

Fertility-Sparing Treatment

For young women with early-stage endometrioid carcinoma who want to preserve fertility:

Showing selected notable trials. View all 244 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions

How do I find endometrial cancer clinical trials I'm eligible for?

Enter your endometrial cancer details into ClinTrialFinder — including MMR/MSI status (dMMR vs pMMR), p53 mutation, HER2 status, and prior treatments. The AI matches you with trials based on your specific profile in minutes.

What endometrial cancer trials are currently recruiting?

There are 244 recruiting interventional trials for endometrial cancer including checkpoint immunotherapy combinations (pembrolizumab, dostarlimab), ADCs (T-DXd, sacituzumab tirumotecan), lenvatinib combinations, and fertility-sparing approaches.

Find Endometrial Cancer Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.

Find Matching Trials